Clinical trials: Fungal Infection
Fungal Infection
CD5CAR-NK Cells for Refractory Invasive Mold Disease
CD5CAR-NK is a first-in-human, pilot, dose-escalation, and single-site study to evaluate the safety of CD5CAR-CBNK in patients with invasive mold diseases (IMD).
- Trial name
- CD5CAR-NK (NCT07454122)
- Testing
- CD5CAR-CBNK
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Liver Cirrhosis, Viral Pneumonia
Liver Cirrhosis Patients With Invasive Pulmonary Aspergillosis: in Depth Understanding Clinical Host Risk Factors
Invasive pulmonary aspergillosis (IPA) is a life-threatening fungal infection of the respiratory system, caused by a specific fungus called Aspergillus species.
- Conditions
- Liver Cirrhosis, Viral Pneumonia, Fungal Infection, Invasive Pulmonary Aspergillosis
- Trial name
- LIVERIPA (NCT07238114)
- Where
- Belgium
- Volunteers
- 450 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pharmacokinetics, Infection, Fungal
PK/PD of Caspofungin in Children Severe Infection
Caspofungin is an anti-fungal drug mainly metabolized by the liver. The pathophysiological status of children with severe infection will affect the metabolism of caspofungin in the body especially in the case of liver…
- Trial name
- NCT04961593
- Testing
- Caspofungin
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Pulmonary Fungal Infection
Posaconazole for Pulmonary Fungal Infection Prophylaxis in Hematopoietic Stem Cell Transplantation Patients
This open, prospective, observational multicenter cohort study aims to evaluate the efficacy, safety as well as the effective serum concentration of Posaconazole for prevention of pulmonary fungal infections in patients with…
- Trial name
- NCT04725942
- Testing
- Oral Posaconazole tablets
- Where
- 4 sites in China
- Volunteers
- 360 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Infection, Infections, Bacterial
Microbial Cell-free Metagenomic Sequencing for Suspected Infections in Adult Immunocompromised Outpatients
This clinical trial is designed to evaluate if adding the Karius Spectrum™ plasma test to usual care diagnostic tests, compared to usual care testing alone, among immunocompromised participants presenting with suspected infection…
- Conditions
- Infection, Infections, Bacterial, Infections, Fungal, Infection Viral
- Trial name
- OPTIMUM (NCT07110636)
- Testing
- Metagenomic plasma-based test for agnostic pathogen detection
- Where
- 6 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Karius, Inc.
Fungal Disease
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
The goal of this observational study is to evaluate the efficacy the favorable response rate and safety of L-AmB(liposomal amphotericin B) for the treatment of br-IFD(breakthrough invasive fungal disease) in Chinese children and…
- Trial name
- NCT07357038
- Testing
- Patients received the Drug: liposomal amphotericin B（AmBisome） for treatment
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Covid19, Aspergillosis
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections.
- Conditions
- Covid19, Aspergillosis, Fungal Infection
- Trial name
- CAPA IFI (NCT04818853)
- Testing
- Observation to monitor patients for these infections
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- University of Alabama at Birmingham
Pyothorax, Fungal Infection Lungs
Fungal Empyema Thoracis
Background: Fungal empyema thoracis is a rare but life-threatening pleural infection caused by fungal organisms such as Aspergillus and Candida species.
- Conditions
- Pyothorax, Fungal Infection Lungs, Pleural Empyema
- Trial name
- NCT07337993
- Testing
- pleural lavage followed by surgery, Decortication, Conservative Arm
- Where
- Pakistan
- Volunteers
- 50 people
- Sponsor
- University of Health Sciences Lahore
Invasive Fungal Disease, Critical Illness
De-escalation - Antifungal Treatment Immunocompromised Patients
A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistance, and high cost.
- Trial name
- D-ATFIM (NCT03774316)
- Where
- France
- Volunteers
- 275 people
- Sponsor
- University Hospital, Lille
Fungal Infection, Vascular Grafting
Fungal Vascular Graft Infections, French Multicenter Retrospective Study
Fungal vascular graft and endograft infections (VGEIs) are rare but life-threatening infections. Best therapeutic management is unknown.
- Trial name
- FUNGIVAS (NCT07143409)
- Testing
- epidemiology and medical treatment strategies
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Bordeaux
Enterobacterial Infections, Oncologic Disease
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial…
- Conditions
- Enterobacterial Infections, Oncologic Disease, Inflammatory Disease, Invasive Fungal Infections
- Trial name
- NCT05611892
- Testing
- 18F-FDS PET/CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Candidiasis, Fungal Infection
PTX3-targeted Antifungal Prophylaxis
This is a prospective genetically-stratified randomized double-blind event-driven multicentre clinical trial to assess the efficacy of posaconazole-based antifungal prophylaxis allocation strategies for patients with acute…
- Conditions
- Candidiasis, Fungal Infection, Acute Myeloid Leukemia, Genetic Predisposition
- Trial name
- PTX3AML (NCT03828773)
- Testing
- Posaconazole, Fluconazole
- Where
- 9 sites in Belgium, France and 1 more
- Volunteers
- 410 people
- Sponsor
- Bochud Pierre-Yves
Invasive Fungal Disease, Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium
Immunomonitoring of Mold Invasive Infections
Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a…
- Trial name
- IMMUNOFIL (NCT06285188)
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Otomycosis, Fungal Ear Infection
Terbinafine Hydrochloride for the Treatment of Otomycosis
Otomycosis is a fungal infection of the ear that often causes itching, pain, ear discharge, and hearing problems. It is more common in hot and humid climates and in people with risk factors such as diabetes, frequent use of…
- Trial name
- NCT07152327
- Testing
- Terbinafine Hydrochloride Cream
- Volunteers
- 50 people
- Sponsor
- Assiut University
Invasive Fungal Infections
Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds
This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).
- Trial name
- AEGIS (NCT04240886)
- Testing
- fosmanogepix
- Where
- 15 sites in United States, Belgium and 2 more
- Volunteers
- 21 people
- Sponsor
- Basilea Pharmaceutica
Fungal Infection
Study to Assess Safety, Tolerability and Pharmacokinetics of APX001 Administered by Intravenous Infusion to Healthy Subjects
First In Human (FIH), randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) escalation study of approximately 80 subjects.
- Trial name
- NCT02956499
- Testing
- APX001 single dose 1, APX001 single dose 2, APX001 single dose 3
- Where
- 2 sites in Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Fungal Infection
Safety, Pharmacokinetics, Bioavailability, Food Effect, Drug-Drug Interaction Study of APX001 Administered Orally
This is a Phase l double-blind, placebo-controlled, randomized study to investigate the safety, tolerability, pharmacokinetics, bioavailability and food effect of single doses of APX001 administered intravenously and orally…
- Trial name
- NCT02957929
- Testing
- APX001 single IV dose, APX001 single oral dose 1, APX001 single oral dose 2
- Where
- 2 sites in Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Basilea Pharmaceutica
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Invasive Fungal Infections
Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions
This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.
- Trial name
- SPECIFIC (NCT06105411)
- Testing
- 68Ga-labelled TAFC PET/CT scan
- Where
- Australia
- Volunteers
- 10 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Invasive Fungal Disease
Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days…
- Trial name
- NCT07135778
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China